Patents by Inventor Chian-Fang Hung

Chian-Fang Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use Of Disulfiram For Treating Infection Of SARS-COV-2
    Publication number: 20210386695
    Abstract: The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram, and a method for inhibiting an activity of a papain-like protease (PLpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram. A method for inhibiting a replication or an infection of a SARS-CoV-2 in a cell includes contacting the cell with a sufficient concentration of disulfiram and a medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of disulfiram are also provided.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 16, 2021
    Applicant: China Medical University
    Inventors: Chang-Hai Tsai, Mien-chie Hung, Yeh Chen, Wen-Hao Yang, Chia-shin Yang, Yu-Lin Hung, Yu-Chuan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung, Hsiao-Fan Chen, Wen-Chi Su, Wei-Jan Wang
  • Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof
    Publication number: 20210330661
    Abstract: The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 28, 2021
    Applicant: China Medical University
    Inventors: Mien-Chie Hung, Yeh Chen, Wen-Hao Yang, Chia-Shin Yang, Yu-Lin Hung, Yu-Quan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung